Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02331173 · ClinicalTrials.gov registry record

Clinical Evaluation of Patients With X-linked Retinoschisis

A clinical trial, sponsored by Beacon Therapeutics.

Completed
Registry status
66
Enrollment target

NCT02331173 is a clinical trial that has completed, run by Beacon Therapeutics. The registered enrollment target is 66 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02331173 has completed, sponsored by Beacon Therapeutics.

COMPLETED
Registry status
66 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate subjects with X-linked retinoschisis in a clinical setting to collect data on disease progression.

Interventions

  • DRUG Dorzolamide 2% TID or brinzolamide 1% TID

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2012-11
Est. Completion 2016-10

Sponsor

Beacon Therapeutics

12 total trials

What the Registry Record Tells You About NCT02331173

The ClinicalTrials.gov registry entry for NCT02331173 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beacon Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Dorzolamide 2% TID or brinzolamide 1% TID is the first listed.

NCT02331173 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02331173 about?

NCT02331173 is a clinical study titled "Clinical Evaluation of Patients With X-linked Retinoschisis". The purpose of this study is to evaluate subjects with X-linked retinoschisis in a clinical setting to collect data on disease progression.

What is the current status of trial NCT02331173?

This trial is currently completed. The enrollment target is 66 participants. The study started on 2012-11. Estimated completion is 2016-10.

What interventions are being tested in trial NCT02331173?

The interventions under investigation include: Dorzolamide 2% TID or brinzolamide 1% TID (DRUG).

Who is sponsoring clinical trial NCT02331173?

This trial is sponsored by Beacon Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.